Zacks Research Predicts Reduced Earnings for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Stock analysts at Zacks Research cut their Q3 2025 earnings per share estimates for shares of Avanos Medical in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $0.41 per share for the quarter, down from their prior estimate of $0.57. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s Q4 2025 earnings at $0.53 EPS and FY2025 earnings at $1.64 EPS.

Separately, StockNews.com lowered shares of Avanos Medical from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 3rd.

Avanos Medical Price Performance

Shares of AVNS opened at $19.37 on Monday. Avanos Medical has a one year low of $17.39 and a one year high of $25.36. The stock’s fifty day moving average is $21.73 and its 200-day moving average is $21.56. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. The firm has a market capitalization of $890.25 million, a price-to-earnings ratio of 56.97 and a beta of 0.92.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AVNS. Tidal Investments LLC bought a new position in shares of Avanos Medical during the 1st quarter valued at about $439,000. Boston Partners acquired a new position in Avanos Medical in the first quarter worth approximately $571,000. Quest Partners LLC acquired a new position in Avanos Medical in the second quarter worth approximately $444,000. Deerfield Management Company L.P. Series C bought a new position in shares of Avanos Medical in the second quarter valued at $551,000. Finally, AQR Capital Management LLC lifted its position in shares of Avanos Medical by 21.0% during the 2nd quarter. AQR Capital Management LLC now owns 146,983 shares of the company’s stock valued at $2,875,000 after acquiring an additional 25,467 shares during the last quarter. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.